# MonumenTAL-3 (NCT05455320)

> A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05455320
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Talquetamab; Daratumumab; Pomalidomide; Dexamethasone
- Enrollment: 864
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- X threads: 30
- YouTube: 25
- Podcasts: 14
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=monumental-3-nct05455320

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05455320", "email": "<work email>"}; the inbox owner confirms by the emailed link.